Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware

Microsoft Corp.Microsoft Corp. (Nasdaq "MSFT") has signed an agreement with Merck & Co. Inc. to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc. The deal allows Microsoft to incorporate genetic, genomic, metabolomic and proteomics data management software into the Microsoft Amalga Life Sciences platform for enhanced translational research capabilities. In addition, Microsoft will establish a strategic relationship with Merck to enhance the Amalga Life Sciences platform to meet emerging pharmaceutical research needs.

Under the terms of the agreement, Merck will become a customer of the Microsoft Amalga Life Sciences 2009 platform and also will provide strategic input to Microsoft on the direction and evolution of new solutions incorporating Rosetta Biosoftware technologies. The software platform will help drive improvements in Merck's already advanced research capabilities.

"This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology. In addition, we look forward to collaborating with Microsoft to develop new bioinformatic solutions to enable and expedite drug discovery and development," said Rupert Vessey, vice president, Merck Research Laboratories. "This is part of our previously announced strategy designed to improve the effectiveness and efficiency of our Basic Research operations to ensure long-term pipeline productivity."

"We're excited to collaborate with Merck and augment the capabilities of Amalga Life Sciences with the complementary assets of Rosetta Biosoftware," said Peter Neupert, corporate vice president, Health Solutions Group, Microsoft. "The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine."

Introduced in April 2009, Microsoft Amalga Life Sciences is a new software platform designed to transform health and life sciences research data into the critical knowledge needed for the discovery of new treatments. The platform helps organizations across the life sciences spectrum accelerate research and discovery efforts by automating the management and analysis of massive, heterogeneous research data. This gives scientists and researchers the opportunity to redesign, manage and control research processes to increase productivity, reduce errors and improve decision-making.

The deal is expected to close at the end of June 2009, and the new Amalga Life Sciences platform incorporating Rosetta Biosoftware technologies is slated to be available in early 2010. Microsoft is pursuing hiring Rosetta Biosoftware employees who can fill roles that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences platform. Until the deal is closed, Rosetta Biosoftware will continue to operate as a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck.

Related news articles:

About Microsoft in Health
Microsoft is committed to improving health around the world through software innovation. Over the past 12 years Microsoft has steadily increased its investments in health, with a focus on addressing the challenges of health providers, health and social services organizations, payers, consumers, and life sciences companies worldwide. Microsoft closely collaborates with a broad ecosystem of partners and develops its own powerful health solutions, such as Amalga and HealthVault. Together, Microsoft and its industry partners are working to advance a vision of unifying health information and making it more readily available, ensuring the best quality of life and affordable care for everyone.

About Microsoft
Founded in 1975, Microsoft (Nasdaq "MSFT") is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

Most Popular Now

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

North West Anglia Works with Clinisys to…

North West Anglia NHS Foundation Trust has replaced two, legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...

Standing Up for Health Tech and SMEs: Sh…

AS the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small and innovative companies, by having...

GPT-4 Matches Radiologists in Detecting …

Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology reports, according to research published in Radiology, a journal of the Radiological Society of North America...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Experts Propose Specific and Suited Guid…

Current Artificial Intelligence (AI) models for cancer treatment are trained and approved only for specific intended purposes. GMAI models, in contrast, can handle a wide range of medical data including...

A Record Year with More than 800 Exhibit…

9 - 11 April 2024, Berlin, Germany. DMEA 2024 kicks off today, focusing on the key issues in the digital transformation of the healthcare system. From now until 11 April over...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...